Ottawa, Canada
Ottawa, Canada

Time filter

Source Type

On Thursday, December 01, 2016, the Toronto Exchange Composite Index was down 0.37%, finishing the day at 15,027.53. The TSX Venture Composite Index, on the other hand, closed at 739.54, up 0.35%. Additionally, the Healthcare index was down by 3.61%, ending the session at 69.09. Active Wall St. has initiated research reports on the following equities: Nuvo Pharmaceuticals Inc. (TSX: NRI), Acerus Pharmaceuticals Corporation (TSX: ASP), and Avivagen Inc. (TSX-V: VIV). Register with us now for your free membership and research reports at: http://www.activewallst.com/register/. On Thursday, shares in Mississauga, Canada-based Nuvo Pharmaceuticals Inc. recorded a trading volume of 2,209 shares. The stock ended the day 0.71% higher at $5.66. Nuvo Pharma's stock has gained 2.72% in the last one month and 16.29% in the previous one year. The Company is trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $6.85 is above its 50-day moving average of $6.12. Shares of the Company, which operates as a life sciences company, are trading at PE ratio of 23.01. See our research report on NRI.TO at: http://www.activewallst.com/registration-3/?symbol=NRI. On Thursday, shares in Mississauga, Canada headquartered Acerus Pharmaceuticals Corp. ended the session 7.14% lower at $0.13 with a total volume of 240,250 shares traded. Shares of the Company, which focuses on developing, manufacturing, marketing, and distributing pharmaceutical products for male hypogonadism, women's hormone replacement therapy, and female sexual dysfunction in Canada, are trading below its 50-day and 200-day moving averages. Further, the stock's 50-day moving average of $0.16 is greater than its 200-day moving average of $0.15. The complimentary research report on ASP.TO at: http://www.activewallst.com/registration-3/?symbol=ASP. Ottawa, Canada headquartered Avivagen Inc.'s stock finished Thursday's session flat at $0.13 with a total volume of 1.43 million shares traded. Avivagen's shares have rallied 85.71% in the past one year. Shares of the Company, which designs, develops, manufactures, markets, and supports natural health products for livestock and companion animals in Canada, the US, Europe, and internationally, are trading below its 50-day moving average. Avivagen's 50-day moving average of $0.16 is above its 200-day moving average of $0.13. Register for free and access the latest research report on VIV.V at: http://www.activewallst.com/registration-3/?symbol=VIV. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


LONDON, UK / ACCESSWIRE / February 16, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Drug Manufacturers industry. Companies recently under review include Nuvo Pharmaceuticals, Acerus Pharmaceuticals, and Avivagen. Get all of our free research reports by signing up at: On Wednesday, February 15, 2017, the Toronto Exchange Composite Index was up 0.37%, finishing the day at 15,844.95. The TSX Venture Composite Index, on the other hand, closed at 838.14, up 0.34%. Additionally, the Healthcare index was up by 3.22%, ending the session at 77.28. Active Wall St. has initiated research reports on the following equities: Nuvo Pharmaceuticals Inc. (TSX: NRI), Acerus Pharmaceuticals Corporation (TSX: ASP), and Avivagen Inc. (TSXV: VIV). Register with us now for your free membership and research reports at: On Wednesday, shares in Mississauga, Canada-based Nuvo Pharmaceuticals Inc. recorded a trading volume of 26,248 shares, which was higher than their three months' average volume of 11,539 shares. The stock ended the day 1.60% lower at $5.54. Nuvo Pharma's stock has advanced 1.47% in the last one month and 12.80% in the previous one year. The Company's shares are trading above its 50-day moving average. The stock's 200-day moving average of $6.31 is above its 50-day moving average of $5.51. Shares of the Company, which operates as a life sciences company, are trading at PE ratio of 1,108.00. See our research report on NRI.TO at: Mississauga, Canada headquartered Acerus Pharmaceuticals Corp.'s stock finished Wednesday's session flat at $0.13 with a total volume of 462,169 shares traded. Over the last one month and the previous three months, Acerus Pharma's shares have rallied 6,971.43% and 7,515.38%, respectively. Furthermore, the stock has rallied 2,202.33% in the past one year. The Company's shares are trading below its 50-day and 200-day moving averages. Acerus Pharma' 50-day moving average of $1.29 is above its 200-day moving average of $0.44. Shares of the Company, which focuses on developing, manufacturing, marketing, and distributing pharmaceutical products for male hypogonadism, women's hormone replacement therapy, and female sexual dysfunction in Canada, are trading at a PE ratio of 9.29. The complimentary research report on ASP.TO at: Ottawa, Canada headquartered Avivagen Inc.'s stock closed the day 4.55% lower at $0.10. The stock recorded a trading volume of 510,000 shares, which was above its three months' average volume of 372,163 shares. Shares of the company, which develops and commercializes various products to replace antibiotics in livestock feeds to optimize the health and growth of the animals by supporting the animal's own health defenses, are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $0.15 is greater than its 50-day moving average of $0.12. Get free access to your research report on VIV.V at: Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Burton G.W.,Avivagen Inc. | Daroszewski J.,Avivagen Inc. | Nickerson J.G.,550 University Ave | Johnston J.B.,National Research Council Canada | And 2 more authors.
Canadian Journal of Chemistry | Year: 2014

Carotenoids are reported to have immunological effects independent of vitamin A activity. Although antioxidant activity has been suggested as a basis of action, the ability of carotenoids to autoxidize to numerous non-vitamin A products with immunological activity is an alternative yet to be fully explored. We have undertaken a systematic study of β-carotene autoxidation and tested the product mixture for immunological activity. Autoxidation proceeds predominantly by oxygen copolymerization, leading to a defined, reproducible product corresponding to net uptake of almost 8 molar equivalents of oxygen. The product, termed OxC-beta, empirical formula C40H60O 15 versus C40H56 for β-carotene, contains more than 30% oxygen (w/w) and 85% β-carotene oxygen copolymers (w/w) as well as minor amounts of many C8-C18 norisoprenoid compounds. No vitamin A or higher molecular weight norisoprenoids are present. The predominance of polymeric products has not been reported previously. The polymer appears to be a less polymerized form of sporopollenin, a biopolymer found in exines of spores and pollen. Autoxidations of lycopene and canthaxanthin show a similar predominance of polymeric products. OxC-beta exhibits immunological activity in a PCR gene expression array, indicating that carotenoid oxidation produces non-vitamin A products with immunomodulatory potential. © 2014 Published by NRC Research Press.


Johnston J.B.,National Research Council Canada | Nickerson J.G.,Avivagen Inc. | Daroszewski J.,Avivagen Inc. | Mogg T.J.,Avivagen Inc. | Burton G.W.,Avivagen Inc.
PLoS ONE | Year: 2014

In animals carotenoids show biological activity unrelated to vitamin A that has been considered to arise directly from the behavior of the parent compound, particularly as an antioxidant. However, the very property that confers antioxidant activity on some carotenoids in plants also confers susceptibility to oxidative transformation. As an alternative, it has been suggested that carotenoid oxidative breakdown or metabolic products could be the actual agents of activity in animals. However, an important and neglected aspect of the behavior of the highly unsaturated carotenoids is their potential to undergo addition of oxygen to form copolymers. Recently we reported that spontaneous oxidation of ß-carotene transforms it into a product dominated by ß-carotene-oxygen copolymers. We now report that the polymeric product is biologically active. Results suggest an overall ability to prime innate immune function to more rapidly respond to subsequent microbial challenges. An underlying structural resemblance to sporopollenin, found in the outer shell of spores and pollen, may allow the polymer to modulate innate immune responses through interactions with the pattern recognition receptor system. Oxygen copolymer formation appears common to all carotenoids, is anticipated to be widespread, and the products may contribute to the health benefits of carotenoid-rich fruits and vegetables. © 2014 Johnston et al.


Patent
Avivagen Inc. | Date: 2016-05-13

The invention features compositions, methods, and kits for the administration of an oxidatively transformed carotenoid, or a fractionated component thereof, for use in aquaculture.


Trademark
Avivagen Inc. | Date: 2016-07-11

Adjuvants for use with vaccines; Animal feed additives and supplements; Anti-infective products for veterinary use; Anti-inflammatories; Dietary, nutritionals and food supplements; Nutritional supplements for general health and well-being; Dietary food supplements for general health and well-being; Medicated dermatological preparations and substances; Medicated skin care preparations; Non-medicated additives for animal feed for use as nutritional supplements; Nutritional supplements for supporting immune function; Nutritional supplements for cats, dogs, horses, livestock; Pharmaceutical preparations for treatment of infectious diseases, namely, respiratory infections, eye infections; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations and substances for the treatment of viral, respiratory, gastrointestinal, dermatological, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of bacteria-based diseases or disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment of bacterial infections; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; Pharmaceutical preparations for the prevention and treatment of disorders of the immune system, Pharmaceutical preparations for treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the treatment of inflammatory disorders and diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in gastroenterology; Pharmaceutical products for skin care for animals; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for treating respiratory diseases; Veterinary preparations for treatment of intestinal bacteria; Veterinary pharmaceutical preparations for animals and poultry to give newborn animals and birds a healthy start; Veterinary pharmaceutical preparations for respiratory and reproductive diseases in cattle; Veterinary pharmaceutical preparations for treatment of bacterial infections in dogs; Veterinary pharmaceutical preparations for the treatment of infectious diseases in poultry; Veterinary pharmaceutical preparations for treatment of infectious disease namely, respiratory infections, eye infections, topical infections; Veterinary pharmaceutical preparations for the treatment of infectious diseases, namely, swine dysentery, bacterial enteritis, bluecomb, pneumonia; Veterinary pharmaceutical preparations for the treatment of swine bacterial infectious diseases; Veterinary pharmaceutical preparations for treatment of intestinal bacteria.


Trademark
Avivagen Inc. | Date: 2013-04-02

Veterinary preparations, namely, veterinary preparations for use in the boosting of immune function, veterinary preparations for the reduction of inflammation, and veterinary preparations for the boosting of immune function and the reduction of inflammation concurrently; veterinary preparations, namely, veterinary preparations containing oxidized carotenoids for use in the boosting of immune function, veterinary preparations containing oxidized carotenoids for the reduction of inflammation, and veterinary preparations containing oxidized carotenoids for the boosting of immune function and the reduction of inflammation concurrently; veterinary nutritional supplements, namely, veterinary nutritional supplements for use in the boosting of immune function, veterinary nutritional supplements for use in the reduction of inflammation, and veterinary nutritional supplements for use in the boosting of immune function and reduction of inflammation concurrently; veterinary nutritional supplements containing oxidized carotenoids, namely, veterinary nutritional supplements containing oxidized carotenoids for use in the boosting of immune function, veterinary nutritional supplements containing oxidized carotenoids for use in the reduction of inflammation, and veterinary nutritional supplements containing oxidized carotenoids for use in the boosting of immune function and reduction of inflammation concurrently; veterinary preparations and nutritional supplements containing oxidized carotenoids, namely, veterinary preparations and nutritional supplements containing oxidized carotenoids for use in the improvement of skin and coat quality, veterinary preparations and nutritional supplements containing oxidized carotenoids for use in the improvement of gastrointestinal conditions and functions, veterinary preparations and nutritional supplements containing oxidized carotenoids for use in the treatment of joint condition and function, and veterinary preparations and nutritional supplements containing oxidized carotenoids for use in the boosting of immune function; veterinary preparations and nutritional supplements containing oxidized carotenoids for the boosting of immune function in animals, namely, in dogs, cats, horses and ornamental fish; veterinary preparations and nutritional supplements containing oxidized beta-carotene for the boosting of immune function in animals, namely, in dogs, cats, horses and ornamental fish; veterinary preparations and nutritional supplements containing oxidized carotenoids for the reduction of inflammation in animals, namely, in dogs, cats, horses and ornamental fish; veterinary preparations and nutritional supplements containing oxidized beta-carotene for the reduction of inflammation in animals, namely, in dogs, cats, horses and ornamental fish; veterinary preparations and nutritional supplements containing oxidized carotenoids for the boosting of immune function and reduction of inflammation concurrently in animals, namely, in dogs, cats, horses and ornamental fish; veterinary preparations and nutritional supplements containing oxidized beta-carotene for the boosting of immune function and reduction of inflammation concurrently in animals, namely, in dogs, cats, horses and ornamental fish.


PubMed | Avivagen Inc. and University of Prince Edward Island
Type: Journal Article | Journal: Journal of agricultural and food chemistry | Year: 2016

We reported previously that the spontaneous oxidation of -carotene and other carotenoids proceeds predominantly by formation of carotenoid-oxygen copolymers and that -carotene copolymers exhibit immunological activity, including priming innate immune function and limiting inflammatory processes. Oxidative loss of carotenoids in fruits and vegetables occurs during processing. Here we report evidence for the occurrence of associated analogous copolymer compounds. Geronic acid, an indirect, low molecular weight marker of -carotene oxidation at 2% of -carotene copolymers, is found to occur in common fresh or dried foods, including carrots, tomatoes, sweet potatoes, paprika, rosehips, seaweeds, and alfalfa, at levels encompassing an approximately thousand-fold range, from low ng/g in fresh foods to g/g in dried foods. Copolymers isolated from several dried foods reach mg/g levels: comparable to initial carotenoid levels. In vivo biological activity of supplemental -carotene copolymers has been previously documented at g/g levels, suggesting that some foods could have related activity.


Trademark
Avivagen Inc. and Chemaphor Inc. | Date: 2010-12-15

Nutritional supplements for animals, not for use as topical skin care or for the treatment of acne, and sold only by veterinarians, in pet stores, or on websites directed to goods for animals.


Trademark
Avivagen Inc. | Date: 2016-08-03

Nutritional supplements, namely, nutritional supplements for animals to improve overall health, hair coat, demeanor and mobility, for the repair and regeneration of joints and ligaments, to enhance immunity; Adjuvants for use with vaccines; Animal feed additives and supplements; Anti-infective products for veterinary use; Anti-inflammatories; Dietary, nutritionals and food supplements; Nutritional supplements for general health and well-being; Dietary food supplements for general health and well-being; Medicated dermatological preparations and substances; Medicated skin care preparations; Non-medicated additives for animal feed for use as nutritional supplements; Nutritional supplements for supporting immune function; Nutritional supplements for cats, dogs, horses, livestock; Pharmaceutical preparations for treatment of infectious diseases, namely, respiratory infections, eye infections; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations and substances for the treatment of viral, respiratory, gastrointestinal, dermatological, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of bacteria-based diseases or disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment of bacterial infections; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; Pharmaceutical preparations for the prevention and treatment of disorders of the immune system, Pharmaceutical preparations for treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the treatment of inflammatory disorders and diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in gastroenterology; Pharmaceutical products for skin care for animals; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for treating respiratory diseases; Veterinary preparations for treatment of intestinal bacteria; Veterinary pharmaceutical preparations for animals and poultry to give newborn animals and birds a healthy start; Veterinary pharmaceutical preparations for respiratory and reproductive diseases in cattle; Veterinary pharmaceutical preparations for treatment of bacterial infections in dogs; Veterinary pharmaceutical preparations for the treatment of infectious diseases in poultry; Veterinary pharmaceutical preparations for treatment of infectious disease namely, respiratory infections, eye infections, topical infections; Veterinary pharmaceutical preparations for the treatment of infectious diseases, namely, swine dysentery, bacterial enteritis, bluecomb, pneumonia; Veterinary pharmaceutical preparations for the treatment of swine bacterial infectious diseases; Veterinary pharmaceutical preparations for treatment of intestinal bacteria.

Loading Avivagen Inc. collaborators
Loading Avivagen Inc. collaborators